Abstract
To control the SARS-CoV-2 pandemic and future pathogen outbreaks requires an understanding of which non-pharmaceutical interventions are effective at reducing transmission. Observational studies, however, are subject to biases, even when there is no true effect. Cluster randomized trials provide a means to conduct valid hypothesis tests of the effect of interventions on community transmission. While they may only require a short duration, they often require large sample sizes to achieve adequate power. However, the sample sizes required for such tests in an outbreak setting are largely undeveloped and the question of whether these designs are practical remains unanswered. We develop approximate sample size formulae and simulation-based sample size methods for cluster randomized trials in infectious disease outbreaks. We highlight key relationships between characteristics of transmission and the enrolled communities and the required sample sizes, describe settings where cluster randomized trials powered to detect a meaningful true effect size may be feasible, and provide recommendations for investigators in planning such trials. The approximate formulae and simulation banks may be used by investigators to quickly assess the feasibility of a trial, and then more detailed methods may be used to more precisely size the trial. For example, we show that community-scale trials requiring 220 clusters with 100 tested individuals per cluster are powered to identify interventions that reduce transmission by 40% in one generation interval, using parameters identified for SARS-CoV-2 transmission. For more modest treatment effects, or settings with extreme overdispersion of transmission, however, much larger sample sizes are required.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
CJEM and JAH were supported by the Princeton Catalysis Initiative.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The simulated data, code, and results that support the findings of this study are openly available in GitHub at http://www.github.com/jsheen/NPI
